Vincent T. Mileto Named to NJBIZ 2025 People to Watch in Health Care
Orcosa
  • Technology
    Technology
    • RITe™ Platform

      Our breakthrough, proprietary technology platform engineered to enhance drug absorption

    • Capabilities

      End-to-end, in-house control of formulation, development, and manufacturing capabilities

  • Research
    Research
    • ORAVEXX™ Research + Development

      Our proprietary cannabinoid composition for the management of pain and inflammation

    • Research Partners

      Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials

    • About Cannabidiol

      Learn more about cannabidiol from the medical community and regulators

  • Company
    Company
    • About Us

      We are modernizing the way medicines are taken

    • Our Team

      Experts in drug development and delivery, manufacturing, and commercialization

  • News
    News
    • In the News

      Recent media coverage regarding Orcosa

    • Press Releases and Blog Posts

      Company news and announcements

  • Careers
    Careers
Contact

Press Releases
and Blog Posts

Jul 22, 2022
Statement on Enrollment of First Patient in NYU Langone Health’s Phase 2 Clinical Trial Utilizing ORAVAEXX™
Jul 15, 2022
Orcosa Appoints Andrew C. von Eschenbach, M.D. and Former Commissioner of the FDA, as Senior Advisor
Jul 15, 2022
Orcosa Announces Positive Results from Phase 1/2 Clinical Trial Utilizing ORAVEXX™ to be Presented at American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting
Mar 25, 2022
Orcosa Comments on Positive Results of NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORAVEXX™
« Previous 1 2 3 4 5 Next »
  • Technology
  • Research
  • Company
  • Careers
Orcosa
© 2025 Orcosa. All rights reserved.
  • Privacy Policy
  • Accessibility Statement